Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Howard Kaufman, Jeffery Scott Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D'Angelo, Kent C. Shih, Celeste Lebbe, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Kevin M. Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem
Institutions: Rutgers Cancer Institute, Moffitt Cancer Center, Angeles Clinic and Research Institute, University of Washington Medical Center, University of Lübeck, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, Hôpital Saint-Louis, Washington University in St. Louis, Instituto Nazionale Tumori Regina Elena, National Cancer Institute, University of Colorado Anschutz, University of Colorado Denver, Harvard University, Dana-Farber Cancer Institute, EMD Serono, Inc. (United States), Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Seattle Cancer Care Alliance, University of Washington
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2461902566